Please use this identifier to cite or link to this item:
Title: Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations
Authors: Sarin, S.K.
Kumar, A.
Angus, P.W.
Baijal, S.S.
Baik, S.K.
Bayraktar, Y.
Chawla, Y.K.
Choudhuri, G.
Chung, J.W.
de Franchis, R.
de Silva, H.J.
Garg, H.
Garg, P.K.
Helmy, A.
Hou, M.C.
Jafri, W.
Jia, J.D.
Lau, G.K.
Li, C.Z.
Lui, H.F.
Maruyama, H.
Pandey, C.M.
Puri, A.S.
Rerknimitr, R.
Sahni, P.
Saraya, A.
Sharma, B.C.
Sharma, P.
Shiha, G.
Sollano, J.D.
Wu, J.
Xu, R.Y.
Yachha, S.K.
Zhang, C.
Asian Pacific Association for the Study of the Liver (APASL) Working Party on Portal Hypertension.
Issue Date: 2011
Publisher: Springer International
Citation: Hepatology International ; 5(2): pp.607-24
Abstract: BACKGROUND: Acute variceal bleeding (AVB) is a medical emergency and associated with a mortality of 20% at 6 weeks. Significant advances have occurred in the recent past and hence there is a need to update the existing consensus guidelines. There is also a need to include the literature from the Eastern and Asian countries where majority of patients with portal hypertension (PHT) live. METHODS: The expert working party, predominantly from the Asia-Pacific region, reviewed the existing literature and deliberated to develop consensus guidelines. The working party adopted the Oxford system for developing an evidence-based approach. Only those statements that were unanimously approved by the experts were accepted. RESULTS: AVB is defined as a bleed in a known or suspected case of PHT, with the presence of hematemesis within 24 h of presentation, and/or ongoing melena, with last melanic stool within last 24 h. The time frame for the AVB episode is 48 h. AVB is further classified as active or inactive at the time of endoscopy. Combination therapy with vasoactive drugs (<30 min of hospitalization) and endoscopic variceal ligation (door to scope time <6 h) is accepted as first-line therapy. Rebleeding (48 h of T (0)) is further sub-classified as very early rebleeding (48 to 120 h from T (0)), early rebleeding (6 to 42 days from T (0)) and late rebleeding (after 42 days from T (0)) to maintain uniformity in clinical trials. Emphasis should be to evaluate the role of adjusted blood requirement index (ABRI), assessment of associated comorbid conditions and poor predictors of non-response to combination therapy, and proposed APASL (Asian Pacific Association for Study of the Liver) Severity Score in assessing these patients. Role of hepatic venous pressure gradient in AVB is considered useful. Antibiotic (cephalosporins) prophylaxis is recommended and search for acute ischemic hepatic injury should be done. New guidelines have been developed for management of variceal bleed in patients with non-cirrhotic PHT and variceal bleed in pediatric patients. CONCLUSION: Management of acute variceal bleeding in Asia-Pacific region needs special attention for uniformity of treatment and future clinical trials.
ISSN: 1936-0533 (Print)
1936-0541 (Electronic)
Appears in Collections:Journal/Magazine Articles

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.